Minerva Obstetrics and Gynecology, an esteemed journal published by EDIZIONI MINERVA MEDICA, serves as a vital resource in the field of obstetrics and gynecology. With an ISSN of 2724-606X and an E-ISSN of 2724-6450, this open access journal aims to disseminate high-quality research and clinical studies that address contemporary challenges and advancements in women's health. Since its inception in 2021, Minerva Obstetrics and Gynecology has garnered recognition within the academic community, achieving a commendable Q3 ranking in the 2023 category of Obstetrics and Gynecology, and placing at the 54th percentile among peers in its Scopus rankings. The journal not only facilitates the exchange of innovative ideas but also encourages collaboration among researchers, healthcare professionals, and students from around the globe. With a commitment to excellence, it aims to address significant topics that impact clinical practice, ensuring that practitioners remain informed about the latest evidence-based practices. For researchers and practitioners aiming to contribute to the advancement of gynecological and obstetric medicine, Minerva Obstetrics and Gynecology represents a prominent platform for publication and engagement.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

Reports of Practical Oncology and Radiotherapy is a distinguished open-access journal dedicated to advancing the fields of oncology, radiotherapy, and cancer research. Published by VIA MEDICA since 2001, this journal serves as a critical platform for disseminating innovative research and practical findings that impact clinical practices and patient outcomes. With an emphasis on fostering collaboration and knowledge exchange among researchers, clinicians, and students, the journal has positioned itself within the Q3 and Q4 categories of renowned directories in oncology, radiology, and nuclear medicine as of 2023. Based in Gdansk, Poland, it provides unrestricted access to its articles, ensuring that crucial research reaches a wide audience. This dedication to open access reflects the journal's commitment to transparency and innovation in the fight against cancer, making it an invaluable resource in this vital field of study.

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, published by Lippincott Williams & Wilkins, is a premier academic journal dedicated to the intricate field of gynecological pathology, serving a critical role in advancing the understanding of diseases related to women's reproductive health. Since its inception in 1982, this journal has established itself as a key resource for researchers, clinicians, and students, with a current impact factor that reflects its esteemed reputation; it is ranked in the Q2 category for both Obstetrics and Gynecology, as well as Pathology and Forensic Medicine, signifying its prominence in academic circles. The journal's scope encompasses a wide array of topics, including histopathological findings, diagnostic methodologies, and evolving therapeutic strategies, all pivotal to enhancing patient care. With a steadfast commitment to disseminating high-quality research until the projected year of 2024, the INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY is an essential read for those looking to stay abreast of the latest developments in this vital area of medical science.

Investigative and Clinical Urology is an esteemed open-access journal dedicated to advancing research and clinical practice in the field of urology. Published by the Korean Urological Association, this journal serves as a crucial platform for sharing innovative findings and discussions on urological science, treatments, and technologies. With an ISSN of 2466-0493 and an E-ISSN of 2466-054X, it has established its presence in the academic community since transitioning to open access in 2016. Positioned in the Q2 quartile of urology journals for 2023 and ranked 39th out of 120 in Scopus's urology category, it reflects a strong impact in the field with a 67th percentile ranking. This journal not only facilitates broad accessibility to high-quality research but also fosters collaboration and dialogue among researchers, professionals, and students interested in the latest advancements in urology. Operating from Seoul, South Korea, Investigative and Clinical Urology remains a pivotal resource for anyone seeking to enhance their understanding and practice in urological medicine.

Journal of Gastrointestinal Cancer, published by SPRINGER, stands as a crucial resource in the fields of Gastroenterology and Oncology. With an ISSN of 1941-6628 and E-ISSN of 1941-6636, this journal has been committed to advancing the understanding and treatment of gastrointestinal cancers since its inception in 2007 and is poised to continue until 2024. The journal is recognized in the Q3 quartiles for both Gastroenterology and Oncology as of 2023, reflecting its relevance and contribution to these vital areas of medical research. Despite not being an open-access journal, it offers printed and online subscription options for access, ensuring that valuable research reaches the hands of practitioners, researchers, and students alike. With a focus on disseminating original research, reviews, and case studies, the Journal of Gastrointestinal Cancer plays a pivotal role in fostering ongoing education and discovery in the fight against cancer, promoting better patient outcomes worldwide. The journal is also indexed in Scopus, with notable rankings in the 50th and 45th percentiles for Gastroenterology and Oncology, respectively, further underscoring its scientific merit and credibility in the academic community.